Kyverna Therapeutics, Inc. KYTX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$156.4M-7.6% | -$161.31M-26.5% | -$160.99M-45.5% | -$158.7M-73.2% | -$145.42M-91.6% | ||
| $1.65M-23.4% | $1.8M-15.7% | $1.99M-1.9% | $2.14M+11.8% | $2.15M+19.9% | ||
| $11.09M+34.6% | $10.08M+20.6% | $8.76M+12.9% | $9.47M+94.7% | $8.24M+104% | ||
| -$150.39M-12.5% | -$153.71M-34.5% | -$157.25M-64.2% | -$141.41M-78.1% | -$133.64M-101% | ||
| —— | —— | $538K-73.2% | $638K-70.5% | $1.66M+46.3% | ||
| —— | —— | —— | —— | —— | ||
| —— | $24.7M— | $18.53M— | $12.35M— | $6.18M— | ||
| $141.48M— | $141.17M— | —— | —— | —— | ||
| -$24.68M— | $27.47M— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Kyverna Therapeutics, Inc. generate?
- Kyverna Therapeutics, Inc. (KYTX) generated -$150.4M in operating cash flow over the trailing twelve months.
- What is Kyverna Therapeutics, Inc.'s free cash flow?
- After $538.0K of capital expenditures, Kyverna Therapeutics, Inc.'s free cash flow was -$153.7M over the trailing twelve months, down 32.0% year over year.
- Where does Kyverna Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Kyverna Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.